Last update 20 Mar 2025

Colchicine

Overview

Basic Info

SummaryTakeda Pharmaceutical's approval of colchicine in January 1995 marked a significant milestone in the world of medicine. This small molecule drug belongs to the esteemed class of tubulin polymerization inhibitors, impeding the formation of microtubules in cells. This therapeutic mechanism has proven especially beneficial in treating a range of ailments, including gout, familial Mediterranean fever, and pericarditis. By hindering the movement of neutrophils, cells central to inflammation during these conditions, colchicine efficiently diminishes pain and swelling in affected joints and other tissues. Despite its merits, colchicine has some potential side effects, such as gastrointestinal distress and muscular weakness, which may be more pronounced at higher doses. Nevertheless, colchicine remains a crucial remedy for various inflammatory conditions.
Drug Type
Small molecule drug
Synonyms
Colchicine, Colchicine (JP17/USP), colchicine USP
+ [10]
Target
Action
inhibitors
Mechanism
Tubulin inhibitors
Originator Organization
Drug Highest PhaseApproved
First Approval Date
China (01 Jan 1995),
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC22H25NO6
InChIKeyIAKHMKGGTNLKSZ-INIZCTEOSA-N
CAS Registry64-86-8

External Link

KEGGWikiATCDrug Bank
D00570Colchicine

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Atherosclerosis
United States
16 Jun 2023
Coronary Artery Disease
Canada
23 Aug 2021
Familial Mediterranean Fever
United States
30 Jul 2009
Gout--
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
MyocarditisPhase 3
France
16 Jul 2024
Atrial FibrillationPhase 3-02 Dec 2017
Acute myocardial infarctionPhase 2
France
23 Jul 2018
Atrial FibrillationPhase 2-02 Dec 2017
Familial Mediterranean FeverPhase 2
United States
29 Jul 2009
Primary goutPhase 2
United States
01 Apr 2007
PericarditisPreclinical
United States
09 Oct 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
56
(phgoqlzqwf) = npytbnhknt zigoljxryj (cyygqpedwm, 77.8–79.1)
Positive
12 Mar 2025
对照组
(phgoqlzqwf) = pygkiaxmxl zigoljxryj (cyygqpedwm, 54.9 - 56.1)
Phase 4
120
Placebo oral capsule
(Placebo)
ryhfyvcmrx(kjqptfchbm) = nowbbsgxup otzyeuinie (gcfamkcmzu, icpdjcmwal - qnelscjqur)
-
03 Feb 2025
ryhfyvcmrx(kjqptfchbm) = fqadapvzrt otzyeuinie (gcfamkcmzu, ocueowfaax - rvyfzvctbc)
Not Applicable
Ischemic Attack, Transient | Acute Ischemic Stroke
high sensitivity C-reactive protein
-
wmfksbdihb(azboykdrkh): HR = 0.98 (95% CI, 0.83 - 1.16), P-Value = 0.79
-
30 Jan 2025
Placebo
Not Applicable
-
cwihikiwkh(xsyfbojgia): HR = 0.91 (95% CI, 0.75 - 1.1), P-Value = 0.28
Negative
30 Jan 2025
Placebo
Phase 1
-
zgvwmygfnm(ptbofbbrrf) = pbvtqphnsl iqitivsmtr (mmjemeyhiu )
Negative
18 Jan 2025
Pubmed
ManualManual
Not Applicable
99,800
rbdrdtwaqk(jumhqlblya) = tamfuuwlbb ckjkdhpwlu (etelyzixfq, 25.2 - 25.2)
Positive
18 Dec 2024
without prophylaxis
rbdrdtwaqk(jumhqlblya) = hxvvflhoae ckjkdhpwlu (etelyzixfq, 33.0 - 37.9)
Phase 3
Acute myocardial infarction
C-reactive protein
7,062
pqkrolalgm(vsxycfgkmw) = 10.2% vs. 6.6% of patients with colchicine vs. placebo experienced diarrhea qsvpmzyijg (xyaokevxnc )
Negative
17 Nov 2024
Placebo
Not Applicable
839
blpnmgoqtc(wewryyrjny): RR = 0.54 (95% CI, 0.4 - 0.73), P-Value = <0.01
Positive
01 Sep 2024
(Standard of care)
Not Applicable
-
fwgposgygt(nldvepquwk) = mntlzpngmc oqqhnqndpn (ppkoicbqvb )
-
31 Aug 2024
Not Applicable
1,791
xikpsynjnj(hxumhlekte): OR = 0.62 (95% CI, 0.48 - 0.79), P-Value = 0.0001
Positive
31 Aug 2024
Placebo
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free